Comparative effectiveness of oral therapies targeting the prostacyclin pathway in pulmonary arterial hypertension: A systematic review and network meta-analysis
Vascular Pharmacology · 2024
DOI: 10.1016/j.vph.2024.107280 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Vascular Pharmacology, 2024. Verfasst von Giovanna Manzi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Policlinico Universitario Umberto I, Sapienza University of Rome, 00161…. Hauptthemen laut MEDLINE: Antihypertensive Agents, Hypertension, Pulmonary, Pulmonary Arterial Hypertension. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Oral prostanoids are recommended in patients with pulmonary arterial hypertension (PAH) and an unsatisfactory response to first-line therapy. OBJECTIVE: To compare the effectiveness of oral therapies targeting the prostacyclin pathway in PAH patients. METHODS: An online search of Medline, Cochrane Registry, Scopus and EMBASE libraries (from inception to May, 12,020) was conducted. Eight randomized controlled studies were included in the meta-analysis involving 3023 patients, with 828 receiving oral treprostinil, 607 patients receiving selexipag, 125 patients receiving beraprost, and 1463 patients receiving placebo. RESULTS: Compared to placebo, oral treprostinil (WMD 9.05, 95% CI 3.0280-15.0839, p = 0.0032) and beraprost (WMD 21.98, 95% CI 5.0536-38.9063, p = 0.0109) were associated with a significant increase in 6-min walking distance (6MWD) at follow-up from baseline, whereas selexipag use was associated with a non-significant increase in 6MWD (WMD 15.41, 95% CI -0.6074; 31.4232, p = 0.0593). Compared to placebo, the risk of clinical worsening was significantly lowered by selexipag (RR 0.47, 95% CI 0.35-0.65, p < 0.001) and oral treprostinil (RR 0.65, 95% CI 0.46-0.90, p 0.012), whereas a non-significant reduction of the outcome was related to beraprost use (RR 0.70, 95% CI 0.36-1.38, p 0.31). No significant difference in 6MWD change and clinical worsening reduction were found among oral treprostinil and selexipag. Beraprost use less frequently caused adverse events as compared to selexipag and oral treprostinil. CONCLUSIONS: No differences in 6MWD change, clinical worsening reduction and adverse events rates were found among oral treprostinil and selexipag, resulting in similar efficacy and safety profiles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Policlinico Universitario Umberto I, Sapienza University of Rome, 00161 Rome, Italy.
- Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Policlinico Universitario Umberto I, Sapienza University of Rome, 00161 Rome, Italy. Electronic address: roberto.badagliacca@uniroma1.it.
Zitieren
APA
Manzi, G., Mariani, M. V., Filomena, D., Recchioni, T., Papa, S., Scoccia, G., Badagliacca, R., & Vizza, C. D. (2024). Comparative effectiveness of oral therapies targeting the prostacyclin pathway in pulmonary arterial hypertension: A systematic review and network meta-analysis. Vascular Pharmacology. https://doi.org/10.1016/j.vph.2024.107280
Vancouver
Manzi G, Mariani MV, Filomena D, Recchioni T, Papa S, Scoccia G, et al. Comparative effectiveness of oral therapies targeting the prostacyclin pathway in pulmonary arterial hypertension: A systematic review and network meta-analysis. Vascular Pharmacology. 2024. doi:10.1016/j.vph.2024.107280
BibTeX
@article{Manzi2024,
author = {Manzi, Giovanna and Mariani, Marco Valerio and Filomena, Domenico and Recchioni, Tommaso and Papa, Silvia and Scoccia, Gianmarco and Badagliacca, Roberto and Vizza, Carmine Dario},
title = {Comparative effectiveness of oral therapies targeting the prostacyclin pathway in pulmonary arterial hypertension: A systematic review and network meta-analysis},
journal = {Vascular Pharmacology},
year = {2024},
doi = {10.1016/j.vph.2024.107280}
}
EUVIMED